Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib.
Industry: Health Care
Latest Trade: $14.99 +0.98 (+7.0%)
First Day Return: -17.6%
Return from IPO: -81.3%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/22/2022 |
Offer Price | $5.00 |
Price Range $5.00 - $5.00 | |
Offer Shares (mm) | 1.4 |
Deal Size ($mm) | $7 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/19/2023 |
Offer Price | $5.00 |
Price Range $5.00 - $5.00 | |
Offer Shares (mm) | 1.4 |
Deal Size ($mm) | $7 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Boustead Securities |
Sutter Securities |
more |
Company Data | |
---|---|
Headquarters | Ponte Vedra, FL, United States |
Founded | 2022 |
Employees at IPO | 1 |
Website www.cadrenal.com |